Savara, Inc.

The momentum for this stock is not very good. Savara, Inc. is not a good growth stock. Savara, Inc. is a mediocre stock to choose.
Log in to see more information.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development...
SVRA Fundamental Data by TradingView

News

Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities
Savara (NASDAQ:SVRA) Rating Reiterated by JMP Securities

Ticker Report Savara (NASDAQ:SVRA - Get Free Report)s stock had its "market outperform" rating reiterated by equities research analysts at JMP Securities in a note issued to investors on Monday, Benzinga...\n more…

Buy Rating for Savara Affirmed on Positive Phase 3 Trial Results and Strong Market Potential
Buy Rating for Savara Affirmed on Positive Phase 3 Trial Results and Strong Market Potential

TipRanks Financial Blog In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Savara (SVRA - Research Report), with a price target o...\n more…

Savara announces new data from Pivotal Phase 3 IMPALA-2 trial
Savara announces new data from Pivotal Phase 3 IMPALA-2 trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presente
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presente

Business Wire Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that new data from the Phase 3 IMPALA-2 clinical trial of...\n more…

Savara Announces New Employment Inducement Grant
Savara Announces New Employment Inducement Grant

Business Wire Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On September 5, 2024...\n more…

Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Business Wire Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the H.C. Wainwright...\n more…